Momenta Pharmaceuticals, Inc. (MNTA) SVP Sells $37,965.00 in Stock

Share on StockTwits

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Santiago Arroyo sold 2,531 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $15.00, for a total value of $37,965.00. Following the completion of the transaction, the senior vice president now directly owns 19,272 shares of the company’s stock, valued at $289,080. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Santiago Arroyo also recently made the following trade(s):

  • On Tuesday, April 9th, Santiago Arroyo sold 8,119 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $15.00, for a total value of $121,785.00.
  • On Thursday, February 14th, Santiago Arroyo sold 2,671 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $13.10, for a total value of $34,990.10.

Momenta Pharmaceuticals stock opened at $14.04 on Friday. Momenta Pharmaceuticals, Inc. has a 12 month low of $9.55 and a 12 month high of $32.20. The company has a market capitalization of $1.38 billion, a P/E ratio of -6.92 and a beta of 2.18.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Momenta Pharmaceuticals had a negative net margin of 232.92% and a negative return on equity of 47.74%. The firm had revenue of $4.11 million during the quarter, compared to analysts’ expectations of $10.12 million. During the same quarter in the previous year, the company posted ($0.63) EPS. Momenta Pharmaceuticals’s revenue for the quarter was down 15.3% on a year-over-year basis. As a group, equities analysts expect that Momenta Pharmaceuticals, Inc. will post -1.72 EPS for the current year.

Several research firms have recently issued reports on MNTA. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $16.00 target price on shares of Momenta Pharmaceuticals in a report on Friday, February 22nd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $29.00 target price on shares of Momenta Pharmaceuticals in a report on Friday, February 22nd. Zacks Investment Research raised Momenta Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $17.00 target price for the company in a report on Saturday, April 27th. BTIG Research began coverage on Momenta Pharmaceuticals in a report on Monday, March 18th. They issued a “neutral” rating and a $14.15 target price for the company. Finally, BidaskClub raised Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 29th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Momenta Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $22.23.

Institutional investors have recently bought and sold shares of the stock. Oregon Public Employees Retirement Fund purchased a new position in Momenta Pharmaceuticals in the fourth quarter valued at approximately $37,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Momenta Pharmaceuticals by 41.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,880 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 1,723 shares during the last quarter. Quantamental Technologies LLC purchased a new position in Momenta Pharmaceuticals in the first quarter valued at approximately $68,000. Smith Asset Management Group LP purchased a new position in Momenta Pharmaceuticals in the fourth quarter valued at approximately $99,000. Finally, Amalgamated Bank purchased a new position in Momenta Pharmaceuticals in the fourth quarter valued at approximately $136,000. Institutional investors and hedge funds own 96.82% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Momenta Pharmaceuticals, Inc. (MNTA) SVP Sells $37,965.00 in Stock” was published by Week Herald and is the property of of Week Herald. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://weekherald.com/2019/05/03/momenta-pharmaceuticals-inc-mnta-svp-sells-37965-00-in-stock.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Further Reading: Dividend

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.